Sugi Predict

Sugi Predict / Compounds / SCHEMBL182781

SCHEMBL182781

SCHEMBL182781

CC1(C)OB(c2cccc(S(N)(=O)=O)c2)OC1(C)C

nearest known ligand 0.60

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 16/20 0.60
▸ CA1 P00915 15/20 0.60
▸ CA9 Q16790 14/20 0.60
▸ CA12 O43570 3/20 0.49
▸ CA14 Q9ULX7 3/20 0.49
▸ CA4 P22748 2/20 0.49
▸ CA5A P35218 2/20 0.49
▸ CA3 P07451 1/20 0.49
▸ CA6 P23280 1/20 0.49
▸ CA7 P43166 1/20 0.49
▸ CA5B Q9Y2D0 1/20 0.49
▸ LPL P06858 2/20 0.46
▸ LIPG Q9Y5X9 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3754376 0.85 LIPG (0.47) CA2CA1CA9CA12CA14
SCHEMBL30015709 0.85 LIPG (0.47) CA2CA1CA9CA12CA14
SCHEMBL24365872 0.84 LIPG (0.46) CA2CA1CA9CA12CA14
SCHEMBL14719268 0.83 LIPG (0.51) CA2CA1CA9CA12CA14
SCHEMBL21125667 0.81 LIPG (0.49) CA2CA1CA9CA12CA14
SCHEMBL1682831 0.81 CA1 (0.45) CA2CA1CA9CA12CA14
SCHEMBL29602805 0.81 CA1 (0.45) CA2CA1CA9CA12CA14
SCHEMBL22655961 0.81 LIPG (0.43) CA2CA1CA9CA12CA14
SCHEMBL1674134 0.81 RAB9A (0.44) CA2CA1CA9CA12CA14
SCHEMBL30510865 0.81 RAB9A (0.44) CA2CA1CA9CA12CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719385-A2 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS University of Vermont and State Agricultural College (US) 2026-04-08 — — EP disclosed
US-20260092053-A1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2026-04-02 — — US disclosed
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 — — US disclosed
EP-4681774-A2 KHK INHIBITORS Gilead Sciences, Inc. (US) 2026-01-21 — — EP disclosed
US-20250352550-A1 SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE UNIV MASARYKOVA (CZ) 2025-11-20 — — US disclosed
EP-4313967-B1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2025-11-12 — — EP disclosed
US-12410160-B2 KHK inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 — — US disclosed
EP-4602046-A1 SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE Masarykova Univerzita (CZ) 2025-08-20 — — EP disclosed
EP-3259250-B1 NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS OXFORD DRUG DESIGN LTD (GB) 2025-07-02 — — EP disclosed
US-20250179017-A1 CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) 2025-06-05 — — US disclosed
US-20080182868-A1 Novel chemical compounds SMITHKLINE BEECHAM CORPORATION 2008-07-31 — — US disclosed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 — — WO disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 — — US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 — — WO disclosed
WO-2007025575-A1 O-HYDROXY- AND O-AMINO BENZAMIDE DERIVATIVES AS IKK2 INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-03-08 — — WO disclosed
EP-1620094-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-02-01 — — EP disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
WO-2004100947-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-11-25 — — WO disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179017-A1 CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS PTGER1, PTGER2, CNR2 CA2 430/4885CA1 1483/4885CA9 1985/4885
US-20080182868-A1 Novel chemical compounds HRAS, VHL, TP53 CA2 3853/4885CA1 4823/4885CA9 4445/4885
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 CA2 2101/4885CA1 4351/4885CA9 4378/4885
US-20250352550-A1 SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE FLT3, ROS1, MAP4K2 CA2 4671/4885CA1 4852/4885CA9 4872/4885
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK CA2 2721/4885CA1 4775/4885CA9 3157/4885
US-20260092053-A1 KHK INHIBITORS KHK, SLC5A2, HK1 CA2 2673/4885CA1 4798/4885CA9 2036/4885
US-12410160-B2 KHK inhibitors KHK, KHDRBS1, NADK CA2 3700/4885CA1 4774/4885CA9 3455/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 CA2 369/4885CA1 701/4885CA9 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.